EPAS1 and nonpapillary renal cell carcinoma: Targeting HIF2α therapy has gained considerable attention, and both PT2385117 and PT2977 (recently identified as “MK-6482”) have demonstrated targeted anti-tumor activity in mouse xenograft models of ccRCC as HIF2α inhibitors [79–81].